skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Biotransformation of /sup 14/C-lidamidine in the rat, Cynomolgus monkey and man

Conference · · Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States)
OSTI ID:5450102

Lidamidine (L) (1-(2,6-dimethylphenyl)-3-methyl-amidinourea) is a novel antidiarrheal agent in animals and man. Studies with /sup 14/C-(L) in rats and monkeys have shown that the drug is well absorbed and excreted in urine primarily as metabolites. Less than 10% of the dose was present as parent compound. HPLC was used for the isolation of metabolites from urine of rats and Cynomolgus monkeys given 10 mg/kg intragastric doses of /sup 14/C-(L). The major metabolite in rats was identified by /sup 1/H NMR and FAB mass spectroscopy as the sulfate cojugate of 3-hydroxylidamidine. Ring hydroxylation of lidamidine followed by Phase II conjugation was the major metabolic pathway in monkeys. Excretion of radioactivity in urine of human volunteers receiving 8 mg doses of /sup 14/C-(L) accounted for 98.2 +/- 0.5 (SD)% of the dose. In contrast to the rat and monkey, urinary elimination of (L) in man accounted for 35.2 +/- 5.3 (SD)% of the dose, and the major metabolite was characterized as N-desmethyllidamidine. Para-hydroxylation on the aromatic ring and/or glucuronidation were insignificant metabolic routes in all three species.

Research Organization:
Rorer Group, Inc., Fort Washington, PA
OSTI ID:
5450102
Report Number(s):
CONF-8604222-; TRN: 86-028439
Journal Information:
Fed. Proc., Fed. Am. Soc. Exp. Biol.; (United States), Vol. 45:3; Conference: 70. annual meeting of the Federation of American Society for Experimental Biology, St. Louis, MO, USA, 13 Apr 1986
Country of Publication:
United States
Language:
English